Matrix metalloproteinase 9 (MMP-9): The middle-man of post-myocardial infarction extracellular matrix remodeling

Fouad A. Zouein, Ashley DeCoux, Yuan Tian, Jared A. White, Yu Fang Jin, Merry L. Lindsey

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The substantial involvement of matrix metalloproteinase-9 (MMP-9) in adverse cardiac extracellular matrix (ECM) remodeling makes it one of the most widely investigated MMPs. Mmp-9 functions primarily by directly degrading and activating ECM structural and non-structural molecules to regulate cardiac tissue remodeling. This activity is opposed under physiological conditions by a set of endogenous inhibitors known as tissue inhibitors of metalloproteinases (TIMPS). Following myocardial infarction (MI), this constraint is diminished and MMP-9 tissue and plasma levels acutely increase concomitant with a decline in cardiac function. Mmp-9 loss-of-function experiments in multiple animal models of MI demonstrate an overall beneficial effect and emphasize the importance of MMP-9 inhibition as a therapeutic intervention. This chapter summarizes MMP-9 structure, transcriptional regulation, post-translational modification, and downstream ECM substrates. We also explore the overall important role of MMP-9 in adverse cardiac remodeling post-MI and its potential utility as a pathophysiological biomarker. Finally, we highlight MMP-9 endogenous and pharmacological inhibitors and the challenges that must be overcome to achieve clinical translation. This is a comprehensive review of MMP-9, from its biochemical structure to its potential role in clinical trials, and can serve as an introduction to young researchers who just joined this research area.

Original languageEnglish (US)
Title of host publicationCardiac Fibrosis and Heart Failure
Subtitle of host publicationCause or Effect?
PublisherSpringer International Publishing
Pages237-259
Number of pages23
ISBN (Electronic)9783319174372
ISBN (Print)9783319174365
DOIs
StatePublished - Jan 1 2015

Fingerprint

Matrix Metalloproteinase 9
Extracellular Matrix
Myocardial Infarction
Tissue
Tissue Inhibitor of Metalloproteinases
Biomarkers
Post Translational Protein Processing
Matrix Metalloproteinases
Animals
Animal Models
Research Personnel
Clinical Trials
Pharmacology
Plasmas
Molecules
Substrates
Research

Keywords

  • Cardiac remodeling
  • Collagen
  • ECM substrates
  • Inflammation
  • Myocardial infarction
  • Proteomics
  • Scar formation
  • Tissue inhibitors of metalloproteinases

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Zouein, F. A., DeCoux, A., Tian, Y., White, J. A., Jin, Y. F., & Lindsey, M. L. (2015). Matrix metalloproteinase 9 (MMP-9): The middle-man of post-myocardial infarction extracellular matrix remodeling. In Cardiac Fibrosis and Heart Failure: Cause or Effect? (pp. 237-259). Springer International Publishing. https://doi.org/10.1007/978-3-319-17437-2_13

Matrix metalloproteinase 9 (MMP-9) : The middle-man of post-myocardial infarction extracellular matrix remodeling. / Zouein, Fouad A.; DeCoux, Ashley; Tian, Yuan; White, Jared A.; Jin, Yu Fang; Lindsey, Merry L.

Cardiac Fibrosis and Heart Failure: Cause or Effect?. Springer International Publishing, 2015. p. 237-259.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zouein, FA, DeCoux, A, Tian, Y, White, JA, Jin, YF & Lindsey, ML 2015, Matrix metalloproteinase 9 (MMP-9): The middle-man of post-myocardial infarction extracellular matrix remodeling. in Cardiac Fibrosis and Heart Failure: Cause or Effect?. Springer International Publishing, pp. 237-259. https://doi.org/10.1007/978-3-319-17437-2_13
Zouein FA, DeCoux A, Tian Y, White JA, Jin YF, Lindsey ML. Matrix metalloproteinase 9 (MMP-9): The middle-man of post-myocardial infarction extracellular matrix remodeling. In Cardiac Fibrosis and Heart Failure: Cause or Effect?. Springer International Publishing. 2015. p. 237-259 https://doi.org/10.1007/978-3-319-17437-2_13
Zouein, Fouad A. ; DeCoux, Ashley ; Tian, Yuan ; White, Jared A. ; Jin, Yu Fang ; Lindsey, Merry L. / Matrix metalloproteinase 9 (MMP-9) : The middle-man of post-myocardial infarction extracellular matrix remodeling. Cardiac Fibrosis and Heart Failure: Cause or Effect?. Springer International Publishing, 2015. pp. 237-259
@inbook{7ec58d04a20a4661a54b28bca093d90e,
title = "Matrix metalloproteinase 9 (MMP-9): The middle-man of post-myocardial infarction extracellular matrix remodeling",
abstract = "The substantial involvement of matrix metalloproteinase-9 (MMP-9) in adverse cardiac extracellular matrix (ECM) remodeling makes it one of the most widely investigated MMPs. Mmp-9 functions primarily by directly degrading and activating ECM structural and non-structural molecules to regulate cardiac tissue remodeling. This activity is opposed under physiological conditions by a set of endogenous inhibitors known as tissue inhibitors of metalloproteinases (TIMPS). Following myocardial infarction (MI), this constraint is diminished and MMP-9 tissue and plasma levels acutely increase concomitant with a decline in cardiac function. Mmp-9 loss-of-function experiments in multiple animal models of MI demonstrate an overall beneficial effect and emphasize the importance of MMP-9 inhibition as a therapeutic intervention. This chapter summarizes MMP-9 structure, transcriptional regulation, post-translational modification, and downstream ECM substrates. We also explore the overall important role of MMP-9 in adverse cardiac remodeling post-MI and its potential utility as a pathophysiological biomarker. Finally, we highlight MMP-9 endogenous and pharmacological inhibitors and the challenges that must be overcome to achieve clinical translation. This is a comprehensive review of MMP-9, from its biochemical structure to its potential role in clinical trials, and can serve as an introduction to young researchers who just joined this research area.",
keywords = "Cardiac remodeling, Collagen, ECM substrates, Inflammation, Myocardial infarction, Proteomics, Scar formation, Tissue inhibitors of metalloproteinases",
author = "Zouein, {Fouad A.} and Ashley DeCoux and Yuan Tian and White, {Jared A.} and Jin, {Yu Fang} and Lindsey, {Merry L.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-17437-2_13",
language = "English (US)",
isbn = "9783319174365",
pages = "237--259",
booktitle = "Cardiac Fibrosis and Heart Failure",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Matrix metalloproteinase 9 (MMP-9)

T2 - The middle-man of post-myocardial infarction extracellular matrix remodeling

AU - Zouein, Fouad A.

AU - DeCoux, Ashley

AU - Tian, Yuan

AU - White, Jared A.

AU - Jin, Yu Fang

AU - Lindsey, Merry L.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The substantial involvement of matrix metalloproteinase-9 (MMP-9) in adverse cardiac extracellular matrix (ECM) remodeling makes it one of the most widely investigated MMPs. Mmp-9 functions primarily by directly degrading and activating ECM structural and non-structural molecules to regulate cardiac tissue remodeling. This activity is opposed under physiological conditions by a set of endogenous inhibitors known as tissue inhibitors of metalloproteinases (TIMPS). Following myocardial infarction (MI), this constraint is diminished and MMP-9 tissue and plasma levels acutely increase concomitant with a decline in cardiac function. Mmp-9 loss-of-function experiments in multiple animal models of MI demonstrate an overall beneficial effect and emphasize the importance of MMP-9 inhibition as a therapeutic intervention. This chapter summarizes MMP-9 structure, transcriptional regulation, post-translational modification, and downstream ECM substrates. We also explore the overall important role of MMP-9 in adverse cardiac remodeling post-MI and its potential utility as a pathophysiological biomarker. Finally, we highlight MMP-9 endogenous and pharmacological inhibitors and the challenges that must be overcome to achieve clinical translation. This is a comprehensive review of MMP-9, from its biochemical structure to its potential role in clinical trials, and can serve as an introduction to young researchers who just joined this research area.

AB - The substantial involvement of matrix metalloproteinase-9 (MMP-9) in adverse cardiac extracellular matrix (ECM) remodeling makes it one of the most widely investigated MMPs. Mmp-9 functions primarily by directly degrading and activating ECM structural and non-structural molecules to regulate cardiac tissue remodeling. This activity is opposed under physiological conditions by a set of endogenous inhibitors known as tissue inhibitors of metalloproteinases (TIMPS). Following myocardial infarction (MI), this constraint is diminished and MMP-9 tissue and plasma levels acutely increase concomitant with a decline in cardiac function. Mmp-9 loss-of-function experiments in multiple animal models of MI demonstrate an overall beneficial effect and emphasize the importance of MMP-9 inhibition as a therapeutic intervention. This chapter summarizes MMP-9 structure, transcriptional regulation, post-translational modification, and downstream ECM substrates. We also explore the overall important role of MMP-9 in adverse cardiac remodeling post-MI and its potential utility as a pathophysiological biomarker. Finally, we highlight MMP-9 endogenous and pharmacological inhibitors and the challenges that must be overcome to achieve clinical translation. This is a comprehensive review of MMP-9, from its biochemical structure to its potential role in clinical trials, and can serve as an introduction to young researchers who just joined this research area.

KW - Cardiac remodeling

KW - Collagen

KW - ECM substrates

KW - Inflammation

KW - Myocardial infarction

KW - Proteomics

KW - Scar formation

KW - Tissue inhibitors of metalloproteinases

UR - http://www.scopus.com/inward/record.url?scp=84943406295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943406295&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-17437-2_13

DO - 10.1007/978-3-319-17437-2_13

M3 - Chapter

AN - SCOPUS:84943406295

SN - 9783319174365

SP - 237

EP - 259

BT - Cardiac Fibrosis and Heart Failure

PB - Springer International Publishing

ER -